Article — Adjusted Body Weight Calculator
Adjusted body weight calculator
Adjusted body weight (AjBW) is a dosing weight used for hydrophilic drugs in obese patients. The standard formula is AjBW = IBW + 0.4 × (ABW - IBW), where IBW is the Devine ideal body weight and ABW is the patient's actual body weight. AjBW prevents the overdosing that happens when fat mass is treated as drug-distributing tissue. It is used routinely for aminoglycosides, vancomycin, and unfractionated heparin.
The concept emerged from clinical pharmacy in the 1980s after a wave of nephrotoxicity from aminoglycosides dosed on actual body weight in heavier patients. The fix was to dose on something between IBW and ABW — a weighted average that captures the active drug-distributing tissue without treating excess fat as if it were lean.
What is adjusted body weight
Adjusted body weight is a calculated dosing weight that splits the difference between ideal body weight and actual body weight. Ideal body weight, from the Devine formula, is the height-based estimate of a healthy weight. Actual body weight is what the patient weighs on the scale. AjBW sits between the two, weighted toward IBW by a correction factor — usually 0.4.
Why split the difference? Because most pharmacokinetic data shows that excess adipose tissue contributes some, but not all, to the apparent volume of distribution. Treating fat as fully drug-distributing (dosing on ABW) overdoses the patient. Treating it as inert (dosing on IBW) underdoses them. The empirical evidence, mostly from aminoglycoside studies in the 1980s, settled on roughly 40% of excess weight as the right adjustment for hydrophilic drugs.
The shift from ABW to AjBW for aminoglycoside dosing in obese inpatients reduced nephrotoxicity rates by 60-80% in 1990s hospital pharmacy audits — one of the cleanest pharmacy interventions of that era. The math is simple, the clinical payoff was substantial.
The adjusted body weight formula
The formula has two parts: IBW (from height and sex) and the correction factor times excess weight. Devine IBW is 50 kg for a 5-foot male and 45.5 kg for a 5-foot female, plus 2.3 kg per inch above 5 feet. Excess weight is ABW minus IBW. Multiply that excess by 0.4, add it back to IBW, and you have AjBW.
- AjBW = IBW + 0.4 × (ABW - IBW)
- Devine IBW male = 50.0 + 2.3 × (height_inches - 60)
- Devine IBW female = 45.5 + 2.3 × (height_inches - 60)
- Standard correction factor = 0.4 (aminoglycosides, vancomycin)
- Heparin correction factor = 0.3 (some institutions)
- Conservative correction factor = 0.25 (narrow-index drugs)
- If ABW < IBW = use ABW, not AjBW
How to use the adjusted weight calculator
Enter height (cm or inches), actual body weight (kg or pounds), and sex. Pick the correction factor your drug or institution uses — 0.4 is the default and the most common. The result panel shows AjBW, Devine IBW, BMI, the excess weight (ABW - IBW), and a recommended dosing weight based on BMI band.
A worked example: female, 165 cm (65 in), 110 kg. IBW = 45.5 + 2.3 × 5 = 57 kg. BMI = 110 / 1.65² = 40.4 kg/m² (class III obesity). Excess weight = 110 - 57 = 53 kg. AjBW = 57 + 0.4 × 53 = 78.2 kg. A gentamicin dose at 5 mg/kg on AjBW = 391 mg per day, versus 550 mg if dosed on ABW. That 159 mg difference is the gap between "therapeutic" and "nephrotoxic" for many obese patients.
< 25 ABW25 - 29.9 ABW (most drugs)30 - 39.9 AjBW (factor 0.4)≥ 40 AjBW or IBWDrugs dosed on adjusted body weight
The drugs most often dosed on AjBW in obese adults are aminoglycosides (gentamicin, tobramycin, amikacin) and vancomycin. ASHP vancomycin consensus guidance recommends AjBW initial dosing for patients with BMI greater than 40 and ABW initial dosing below that, with both followed by therapeutic drug monitoring. Unfractionated heparin is often dosed on AjBW with a factor of 0.3 to avoid supratherapeutic anti-Xa levels in obese patients.
Several drug classes do not use AjBW. Propofol, midazolam, and other lipophilic anesthetics dose on total body weight because they distribute into fat. Rocuronium and succinylcholine have their own conventions (IBW and TBW respectively). Low-molecular-weight heparins like enoxaparin are usually capped rather than adjusted. Always check the drug-specific guideline.
Choosing the correction factor
The 0.4 factor is the most common but it is not universal. Some institutions use 0.3 for heparin to avoid bleeding. Aminoglycoside guidelines occasionally suggest 0.25 in the very obese (BMI > 50) to stay closer to IBW. A handful of agents use 0.5 — for example, some sources for cefepime in obesity. The point: the factor is drug-specific, not patient-specific. Look it up for the medication you are dosing.
If your institution publishes a drug-dosing-in-obesity protocol, follow it. Local protocols incorporate institutional pharmacokinetic monitoring, microbiology, and the practical realities of your patient population — they trump generic tables.
Adjusted body weight vs ideal body weight
For the same height and sex, IBW is fixed and AjBW grows with actual weight. A 5'10" male has an IBW of 73 kg. At ABW of 90 kg his AjBW is 73 + 0.4 × 17 = 80 kg. At ABW of 150 kg his AjBW is 73 + 0.4 × 77 = 104 kg. AjBW always falls between IBW and ABW, with the proportion controlled by the correction factor.
AjBW is not static. Patients who lose substantial weight need their AjBW recalculated, particularly between dose adjustments. A patient who drops 20 kg has a lower AjBW and may need a smaller dose to stay in the therapeutic range — and to avoid toxicity from accumulation in patients with reduced clearance.
Limits of the adjusted body weight approach
The AjBW approach is a heuristic, not a measurement. It assumes lean body mass scales linearly with height, which is only roughly true. For high-precision dosing — chemotherapy, immunoglobulin therapy, some critical care drugs — lean body mass from formulas like Janmahasatian or from DEXA is preferred. AjBW also does not account for renal or hepatic dysfunction, which often dominate dose decisions in critically ill patients regardless of body size.
The other limit is that the underlying empirical work focused on aminoglycosides and a handful of other agents. Extrapolating AjBW to a drug that was never studied in obese patients is a leap. When in doubt, consult a clinical pharmacist — particularly for patients with BMI above 40, on multiple weight-based medications, or with renal impairment.